Astrana Health
NASDAQ: ASTH
$44.92 ▼ -0.18  (-0.40%)
At close: Jul 17, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap2.44 Mn
P/E0.09
P/S0.00
Div. Yield1.04
ROIC (Qtr)0.00
Total Debt (Qtr)1.03 Bn
Revenue Growth (1y) (Qtr)55.56
Add ratio to table…

About

Astrana Health, Inc. is a provider centric technology powered risk bearing healthcare company that operates an integrated healthcare delivery platform enabling physicians to participate in value based care arrangements. The company leverages its proprietary end to end technology solutions to support coordinated outcomes based medical care for patients across multiple states. Together with its affiliated physician groups and consolidated entities it serves patients covered by…

Read more ↓
Sector: Healthcare Industry: Medical Care Facilities CIK: 0001083446

Investment Thesis

▲ Bull case
  • Astrana’s AI enabled platform is not a collection of point solutions but a fully integrated operating system that ties together claims processing prior authorization care management and clinical decision support within a single data ontology. This architecture allows the company to capture longitudinal patient data across payer lines and settings which continuously refines its risk prediction models and next best action recommendations. As more members flow through the platform the models become sharper leading to lower medical cost trends and higher gap closure rates without proportional increases in administrative expense. The result is a self reinforcing cycle where better clinical outcomes generate more predictable financial performance and the platform’s value compounds over time.
  • The company has moved approximately 40% of its membership and 80% of its care partners revenue into full risk arrangements well ahead of the original conversion timeline. This shift translates into a higher percentage of premium captured per member while creating strong incentives to manage inpatient utilization and overall cost of care. Early performance of the new full risk cohorts shows medical cost trends tracking at or below the 5.2% blended assumption indicating disciplined underwriting. As these cohorts mature the margin profile is expected to converge with that of partial risk businesses unlocking additional operating leverage and free cash flow generation.
  • Integration of the Prospect acquisition is progressing faster than expected with gross provider retention above 99% and the company tracking toward the high end of its twelve to fifteen million dollar annual synergy target. Beyond cost synergies the combined network offers denser provider coverage and improved access to care which can generate revenue synergies that have not yet been quantified. The ability to onboard Prospect onto the Astrana operating system demonstrates the platform’s scalability and its capacity to assimilate acquired assets without disruption. As the integration continues the company expects to realize additional medical cost improvements and expanded market presence in its expansion geographies.
  • The care enablement business which sells Astrana’s AI powered workflow tools to external provider groups is growing rapidly and carries strong gross and EBITDA margins. This segment not only creates a recurring revenue stream but also serves as a validation of the platform’s utility outside the company’s owned networks. Management has highlighted that the Quality Adjustment Fund (HQAF) contribution remains excluded from guidance due to timing uncertainty but could provide a meaningful uplift to earnings once realized. The combination of internal margin expansion from AI driven efficiencies and external monetization of the platform creates multiple levers for earnings growth that are not fully reflected in current consensus estimates.
  • Net leverage has fallen to approximately 2.3 times on a pro forma trailing twelve month basis and is projected to reach or fall below 2.0 times by year end well ahead of the original 24 month target set after the Prospect transaction. This rapid deleveraging improves the company’s financial flexibility and reduces interest expense pressure on future earnings. Strong free cash flow generation in the first quarter of over sixty four million dollars underscores the durability of the operating model even as integration costs decline. With a healthier balance sheet Astrana can consider opportunistic share repurchases or selective tuck in acquisitions without compromising its deleveraging goals.
▼ Bear case
  • Medicaid membership trends remain a source of uncertainty with disenrollment tracking slightly ahead of the midpoint of the company’s range and acuity benefiting from lower than expected adverse selection which may not persist if enrollment patterns shift. The exchange business experienced attrition ahead of expectations earlier in the year although recent trends show improvement but the sustainability of this reversal is unproven. A sudden increase in adverse selection driven by macroeconomic pressures or changes in subsidy design could erode medical cost performance and increase volatility in earnings. Because the company’s guidance assumes a conservative outlook for these lines any better than expected outcome would be a positive surprise but the downside risk remains material to the overall forecast.
  • While the company reports that approximately 40% of members and 80% of care partners revenue are now in full risk arrangements the transition carries execution risk as the shift to full risk requires changes in provider behavior utilization management and financial oversight. Early cohorts have shown medical cost trends at or below assumptions but there is limited history of how these margins will evolve as the risk base expands and as newer contracts with different payer mixes are added. If the anticipated margin maturation does not occur as expected the company could experience lower than projected EBITDA margins despite higher premium percentages. Furthermore any missteps in care coordination or authorization processes under full risk could lead to increased medical costs and provider dissatisfaction.
  • Integration of Prospect is progressing quickly but the complexity of aligning disparate IT systems provider contracts and clinical workflows across a larger geographic footprint could uncover unforeseen costs or operational friction. The company has disclosed only cost synergies in the twelve to fifteen million dollar range and has not quantified potential revenue synergies leaving upside uncertain. If the integration process encounters delays or requires additional investments the anticipated synergies may be delayed or reduced impacting the earnings outlook. Moreover retaining provider loyalty at the reported above 99% rate may become challenging as the combined entity scales and faces competitive pressures in local markets.
  • Approximately eighty% of Astrana’s revenue continues to originate from California making the company highly exposed to state specific regulatory changes reimbursement rate adjustments and local market dynamics. Any adverse shift in California Medicaid policy or a deterioration in the state’s fiscal health could disproportionately affect earnings compared to a more geographically diversified peer group. While expansion into Texas and Southern Nevada is underway these markets still represent a small fraction of total membership and may take years to reach scale sufficient to meaningfully dilute California concentration. The company’s growth strategy remains dependent on successfully replicating its model outside of its home state which carries execution and market acceptance risks.
  • Management attributes a portion of the seventy basis point year over year improvement in G&A as a percentage of revenue to AI enabled tools but has not provided a precise quantification making it difficult to assess the true incremental benefit of these investments. Competitors with larger scale and deeper pockets are accelerating their own AI initiatives and may eventually narrow the technological gap that Astrana currently enjoys. If the AI driven efficiencies prove to be less durable or easier to replicate than suggested the company’s operating leverage assumptions could be overly optimistic. Additionally the focus on administrative automation may yield diminishing returns once low hanging fruit is captured leaving less room for further G&A compression.

Legal Entity Breakdown of Revenue (2025)

Customer Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 HCA HCA Healthcare, Inc. 87.94 Bn11.251.1548.02 Bn
2 CHE Chemed Corp 18.08 Bn51.687.120.09 Bn
3 THC Tenet Healthcare Corp 16.59 Bn9.740.7713.21 Bn
4 DVA Davita Inc. 15.37 Bn14.021.1010.63 Bn
5 EHC Encompass Health Corp 10.07 Bn654.201.662.57 Bn
6 ENSG Ensign Group, Inc 9.52 Bn27.181.810.14 Bn
7 UHS Universal Health Services Inc 9.19 Bn6.050.524.71 Bn
8 PACS PACS Group, Inc. 6.96 Bn28.551.280.05 Bn